Stay updated with breaking news from Jay Duker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The phase 2 trial failed to show improvement of ≥2-DRSS levels with the vorolanib intravitreal insert in patients with non-proliferative diabetic retinopathy.
Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary...
EyePoint Pharmaceuticals is positioning the drug, EYP-1901, as an alternative to currently available wet AMD therapies.
EyePoint’s stock price vaulted more than 180 percent to $18.56 a share, a gain of $11.90 on the Nasdaq exchange in mid-day trading.